ClinicalTrials.gg
CompletedNCT01874626Updated May 21, 2021

Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain

A Phase 3 interventional study of Placebo and SST-0225 Topical Ibuprofen Cream in Acute Ankle Sprain, sponsored by Strategic Science & Technologies, LLC. Completed at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-05-21.

Sponsored by Strategic Science & Technologies, LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,185 studies in Lymphoma, Follicular with a site in United States — 127 open to participants now, 216 under way, 20 of them phase 3. Lymphoma, Follicular · United States.

Enrollment
85th of 1,015
305 · median 38
Started
2013
with 40 others
Phase 3
105 of 1,185
9 open now
Registered
677th of 1,185
by date

Among the 1,185 studies in Lymphoma, Follicular with a site in United States, this one is the 85th largest by enrollment of the 1,015 interventional ones that give a count, is one of 41 that started in 2013, is one of 105 in phase 3, and was the 677th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

127 of the 1,185 studies in Lymphoma, Follicular with a site in United States are open now. Recruiting first, the newest first:

122 more — sign in →

All 127 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,185 studies in Lymphoma, Follicular with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, multi-center, double-blind, placebo-controlled, multi-dose, parallel-group study. Approximately 300 subjects (150 per group) 16 years of age and older with a current (within 24 hours from Visit 1) Grade I or II ankle sprain, and who meet all eligibility criteria, will be randomized into the study and will receive either the active treatment (SST-0225 ibuprofen cream), or matching placebo. Subjects will apply an amount equivalent to a 4 inch line of investigational product to the affected ankle approximately every 4-6 hours. At Visit 1 two doses will be applied at the site. All subsequent doses of the investigational product will be applied every 4 to 6 hours with a total of 4 doses in a 24 hour period. Duration of treatment with the investigational product is 7 days.

03

Conditions studied

  • Acute Ankle Sprain

Keywords

  • acute ankle sprain
  • Grade I or Grade II
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects ≥16 years of age
  2. Grade I or II acute ankle sprain injury within 24 hours prior to first use of product.

    1. Grade I: when the ligament is stretched but not torn and the anterior talofibular ligament is usually involved. The anterior drawer test is negative
    2. Grade II: moderate sprain, which usually results in partial tears of the ligaments, primarily the anterior talofibular and possibly the calcaneofibular ligament. Ligamentous laxity may be present and there is moderate swelling
  3. At screening (Visit 1), subject reported pain intensity score upon movement of ≥ 5 on a 0-10 Numerical Rating Scale (NRS)
  4. Subject's Assessment of Normal Function/Activity (must be > 2) at screening
  5. Able to comply with the visit schedule
  6. Able to apply the investigational product as directed
  7. Females of must be willing to use an approved method of during study participation. Subjects currently using any of the below mentioned contraception methods, must have used the method for a minimum of three months prior to study enrollment, and must be willing to continue its use (at the same dose) throughout the study.

    1. Effective methods of birth control: e.g. prescription oral, vaginal or transdermal contraceptives; contraceptive implants or injections; intrauterine device; diaphragm/cervical cap/condom with spermicide
    2. Other acceptable methods of birth control include: or amenorrhea for one year, Surgically sterile (hysterectomy, tubal ligation, or oopherectomy), Premenarcheal
  8. Able to speak, read and comprehend English and record requested measurements as outlined in the protocol
  9. Subject must be able to read, understand, sign and date the document (and the subject assent form, if necessary) indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial

Exclusion criteria

-

Exclusion Criteria:

Subjects meeting any of the following criteria will not be entered in the study:

  1. Similar injury of the same joint within the last 6 months
  2. Clinical evidence of complete rupture of ankle ligaments (third degree sprain)
  3. Requirements for bed rest, hospitalization, or surgical intervention for the ankle injury
  4. Evidence of fractures or non-removable full cast of any type
  5. Presence of bilateral occurrence of ankle injury or ipsilateral ankle and/or knee injury
  6. Open wound or infection at site of injury
  7. Significant Skin irritation at the application site;
  8. Use of longer half life NSAID within 12 hours prior to study entry (Appendix 4)
  9. Does not agree to use only supplied product and rescue medication for analgesia during the seven days of the study or expects to require analgesics during the study for pain other than for ankle pain
  10. Presence or history of allergy or intolerance to aspirin, NSAIDs, acetaminophen or any of the in the investigational product (L-Arginine hydrochloride, Glyceryl Stearate, Cetyl Alcohol, Squalane, Xanthan Gum, Isopropyl Myristate, Oleic Acid, Propylene Glycol, Polysorbate -20)
  11. Medical conditions including: peptic ulcer disease; gastrointestinal, renal, or hepatic disease within the past 6 months; clinically significant cardiovascular disease not stable for the past 6 months; uncontrolled hypertension as indicated by systolic blood pressure greater than or equal to 160 mmHg or a diastolic blood pressure greater than or equal to 100 mm Hg; coagulation disorders or hematologic disease; history of seizures; or known, significant, pre-existing conditions that would affect the interpretation of any potential adverse reactions to the study medication
  12. Known alcohol abuse, drug dependency, or history of significant psychiatric illness within the past 12 months
  13. Females who are pregnant or lactating.

    -

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
305 participants (actual)

Study arms

  • Active comparator
    Active

    SST-0225 Topical Ibuprofen Cream (investigational product) Dose: 2.7 grams of cream containing 200 mg ibuprofen

    Drug: SST-0225 Topical Ibuprofen Cream

  • Placebo comparator
    Placebo

    Placebo topical formulation (Reference product)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. 24 Hour SPID

    Tme weighted summed pain intensity on movement difference from baseline over the first 24 hours (SPID24) following the first application of study medication on Day 1

    Time frame: 24 Hours

Secondary outcomes

  1. Time to onset of confirmed perceptible pain relief and onset of meaningful pain relief

    • Time to onset of confirmed perceptible pain relief and onset of meaningful pain relief over the four-hour in-office phase of the study.

    Time frame: First 4 hours

  2. Mean change from baseline in subject reported pain intensity

    • Mean change from baseline in subject reported pain intensity (at rest and on movement) and pain relief (on movement only) as assessed at 15 minutes, 30 minutes, and hourly up to 4 hours following the first application on Day 1.

    Time frame: First 4 hours

  3. Mean change from baseline in pain scores on movement

    • Mean change from baseline in pain scores on movement at hours 6, 8, 10, 12, 20 and 24 hours over the first 24 hours.

    Time frame: First 24 hours

  4. Percent of subjects with > 15%, > 30% and > 50% reductions in pain intensity

    • Percent of subjects with \> 15%, \> 30% and \> 50% reductions in pain intensity from baseline at 24 hours.

    Time frame: First 24 hours

  5. Subject's global evaluation of investigational product

    • Subject's global evaluation of investigational product evaluated at Days 2, 4 and 7 (or End-of-Study) based on a 5 point scale.

    Time frame: 7 days

  6. Use of rescue medication including time to first use

    • Use of rescue medication including time to first use (first 12 hours), proportion of subjects using rescue and amount of rescue medication used.

    Time frame: 7 days

  7. Change from baseline in pain scores on movement

    • Change from baseline in pain scores on movement at time of each dose on Days 2-7.

    Time frame: 7 days

  8. Number and percent of patients with systemic and local (skin) self-reported adverse events

    Number and percent of patients with systemic and local (skin) self-reported adverse events.

    Time frame: 7 days

07

Study locations

1 site
  • Ce3
    Guilford, Connecticut 06437, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Jan 2014, 7 months.

Of 45 industry-sponsored phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 86. This study's 7 months is below that.

Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2012
First posted
Jun 11, 2013
StartActual
Jun 2013
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results delay requested
Feb 5, 2015
Last update
May 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01874626
Lead sponsor
Strategic Science & Technologies, LLC
Responsible party
Sponsor
First posted
Jun 11, 2013
Start date
Jun 2013
Primary completion
Jan 2014
Completion
Jan 2014
Last update
May 21, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion